Evaluation of drotrecogin alpha in adult patients with severe sepsis
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000624
Spanish
Authors' objectives:
This study aims to summarise the available evidence on the use of drotrecogin alpha in adult patients with severe sepsis.
Authors' results and conclusions:
Drotrecogin alpha has shown its benefit in reducing 28-day mortality in some patients with sepsis and multiple organ failure. There is some evidence that this benefit could extend to one year in the subgroup of patients who are more severe, particularly young patients without pre-existing pathology. Note that the use of drotrecogin is a treatment that complements the Severe sepsis and Septic shock care standards (e.g,: abscess drainage, early diagnosis of infections, antibiotic therapy according to culture, etc.)
Authors' recommendations:
The benefit of drotrecogin alpha was established within the context of state-of-the-art intensive care units where all diagnostic and therapeutic measures were assured in the management of these patients. This level of complexity may be compared to, at least, Level 1 intensive care units from the National Program of Quality Assurance, from the National Ministry of Health. It is worth pointing out that few intensive care units today have achieved this level. The benefit of drotrecogin in intensive care units which do not meet these standards is uncertain.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Anti-Inflammatory Agents, Non-Steroidal
- Protein C
- Protein Kinase C
- Recombinant Proteins
- Sepsis
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.